GSK tells in-Pharmatechnologist.com that decision to close Indian API plant was prompted by rising cost of manufacture and availability of third party contractors.
Theorem and Gallus say their new biologics manufacturing partnership is aimed at giving a “leg up” to drugsmakers in emerging markets looking to market products in the US.
Outsourcing-Pharma.com presents its weekly round-up of the latest new and changing faces in the pharmaceutical industry, including news from Parexel, Deloitte and Cerafor.
Chinese CRO Wuxi Pharmatech posted impressive revenue growth for Q2 driven by demand for lab services, but the firm still faced margin pressure due partly to rising labour costs.
Icon has boosted its Phase I translational medicine services in Manchester, UK, in preparation for what it believes will be a boom in the drug development area.
New Human Medicines Regulations came into effect this morning, overhauling the UK's regulations on drug manufacturing, importation, distribution, packaging and pharmacovigilance.
in-PharmaTechnologist.com presents its latest low down of the new faces and changing places in the world of pharmaceuticals, including news from Horizon, Conatus and Akorn.
The US Food and Drug Administration backs pyrogen and endotoxin testing recommendations developed by the USP and AAMI, but has issued a Q&A to set out the regulatory perspective
India’s biostatistics outsourcing market is set to grow 15 per cent in two years thanks to a 50 per cent cost saving compared with the West, according to a new survey.
Bosch Packaging Technology says India is becoming one of its key markets, citing the growing pharma sector as a key driver for the development of its new Goa facility
Tablet technology firm Accu-Break Pharmaceuticals has signed a product development and licensing agreement with Indian generic drugmaker Alembic Pharmaceuticals.
A new formulation of Genetech’s breast cancer drug Herceptin means patients could soon receive treatment via injection, rather than time consuming intravenous drip.
ResearchNurses.co will conduct home visits in clinical trials for three Big Pharma firms after forging an agreement with Nottingham University Hospitals Research and Innovation Department.
Inspectors will be able to visit clinical trial sites unannounced and seize records under new draft guidelines issued by the Indian Central Drugs Standard Control Organisation (CDSCO).
The International Pharmaceutical Excipients Council (IPEC) Americas has welcomed new SFDA excipient quality and supervision regulations, which it says are largely consistent with its own guidelines.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) wants members to suggest changes to tax laws governing pharmaceutical exports ahead of India’s next budget.
Access to patient populations is a bigger deciding factor than low cost when selecting a Phase I service provider, according to ISR’s new quality benchmarking report.
The luggage Team USA took to the London 2012 Olympics was lighter than that carried to previous tournaments thanks to a technology provided by GE Healthcare.
Biopharma manufacturers are putting their supply chains at risk by failing to prepare for emergencies, according to a new study by Best Practices, LLC.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
Parexel may be willing to act as a matchmaker for the small and midsized developers that work with its new BioPharm unit according to COO Mark Goldberg.
Proposed law changes put before the US Senate and the House of Representatives last week seek to eliminate duplicate trials and force sponsors to display all results on Clinical trials.gov website.
Results season is well under way and in-PharmaTechnologist.com is here to bring you the latest as companies announce their chops, changes and plans for the coming quarters.
The Chinese Food and Drug Administration (SFDA) has confirmed that drugmakers and suppliers will take on more responsibility for ensuring excipient quality under new provisions.
AMRI’s once troubled Burlington facility has seen an uptick in new contracts and is showing strong potential for more, according to CEO Thomas D'Ambra.
Dr. Reddy’s may not have as big a hill to climb as some observers suggest to regain customers lost as a result of the closure of its Mexican API plant, according to Barclays.
Outsourcing-Pharma.com presents its latest round up of career moves in the pharmaceutical industry, including news from Theorem, FMC Technologies and EMD Serono.
The World Anti-doping Authority (WADA) wants pharmaceutical manufacturers to identify drug candidates in their pipelines that could be used to cheat in sport.
